Mersana Therapeutics, Inc. Announces Executive Changes
August 16, 2021 at 08:00 am EDT
Share
Mersana Therapeutics, Inc. announced the appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer, effective August 16, 2021. Dr. Misra replaces Michael Kaufman, Ph.D., who is retiring from Mersana after more than five years with the Company. Dr. Kaufman will remain at Mersana to ensure a smooth transition until September 10, 2021. Tushar Misra, Ph.D., was most recently EVP, Head of Technical Development & Manufacturing at Laronde. While at Laronde, he led the process development and support team for end-to-end manufacturing for preclinical and clinical research. Before that, he was SVP, Technical Operations at Wave Life Sciences. Prior to Wave Life Sciences, Dr. Misra worked at Takeda Pharmaceuticals in several positions of increasing seniority, most recently as VP & Head, Global Oncology and Biologics Operations. While at Takeda, he built world-wide manufacturing and supply chain infrastructure for the company’s biologic and oncology commercial products including ADCETRIS® (brentuximab vedotin) and ENTYVIO (vedolizumab). Earlier in his career, he held senior executive leadership roles in Chemistry and Pharmaceutical Sciences at Sunovion Pharmaceuticals, Inc. (previously Sepracor, Inc.).
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.